Τίτλος:
Red blood cell transfusion in surgical cancer patients: Targets, risks, mechanistic understanding and further therapeutic opportunities
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Anemia is present in more than half of cancer patients and appears to be an independent prognostic factor of short- and long-term adverse outcomes. It increases in the advanced period of cancer and perioperatively, in patients with solid tumors who undergo surgery. As a result, allogeneic red blood cell (RBC) transfusion is an indispensable treatment in cancer. However, its safety remains controversial, based on several laboratory and clinical data reporting a linkage with increased risk for cancer recurrence, infection and cancer-related mortality. Immunological, inflammatory and thrombotic reactions mediated by the residual leukocytes and platelets, the stored RBCs per se, the biological response modifiers and the plasticizer of the unit may underlie infection and tumor-promoting effects. Although the causality between transfusion and infection has been established, the effects of transfusion on cancer recurrence remain confusing; this is mainly due to the extreme biological heterogeneity that characterizes RBC donations and cancer context. In fact, the functional interplay between donation-associated factors and recipient characteristics, including tumor biology per se, inflammation, infection, coagulation and immune activation state and competence may synergistically and individually define the clinical impact of each transfusion in any given cancer patient. Our understanding of how the potential risk is mediated is important to make RBC transfusion safer and to pave the way for novel, promising and highly personalized strategies for the treatment of anemia in surgical cancer patients. © 2017 Elsevier Ltd
Συγγραφείς:
Tzounakas, V.L.
Seghatchian, J.
Grouzi, E.
Kokoris, S.
Antonelou, M.H.
Περιοδικό:
Transfusion and Apheresis Science
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
biological response modifier; plasticizer, adverse outcome; anemia; blood clotting; cancer mortality; cancer patient; cancer prognosis; cancer recurrence; erythrocyte preservation; erythrocyte transfusion; human; immunocompetence; immunostimulation; infection; inflammation; leukocyte; perioperative period; personalized medicine; Review; risk assessment; solid malignant neoplasm; surgical patient; thrombocyte; thrombosis; anemia; erythrocyte transfusion; neoplasm; pathology; procedures; risk, Anemia; Erythrocyte Transfusion; Humans; Neoplasms; Risk
DOI:
10.1016/j.transci.2017.05.015
